Ascrinvacumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAscrinvacumab
Drug Alias NameAscrinvacumabum阿司可人单抗阿伐苏单抗PF-03446962PF-3446962 +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionActivin receptor-like kinase 1 inhibitors
TargetsActivin receptor-like kinase 1
Therapy Area/IndicationsSolid tumoursMacular DegenerationLiver Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Koshine Biomedica IncPfizer IncKintor Pharmaceuticals Hong Kong Ltd
Inactive CompaniesDuke University
Active IndicationsSolid tumoursMacular DegenerationLiver Neoplasms +[4] 
Inactive IndicationsColorectal NeoplasmsMesotheliomaNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia